COVID-19 Testing for the Essential Workforce
Learn about our efforts to test people on the front line and how you can help.
We study microRNA-disrupting mutations which function in ways distinct from other known, inherited genetic markers. Our goal is to bring this new class of genetic differences into current prevention strategies. Our first example, the KRAS-variant, is an inherited genetic mutation associated with a family history of cancer, especially breast,1 ovarian,2 lung,3 as well as other cancers,4,5 and multiple cancers in the same individual.6,7
The latest research indicates the KRAS-variant’s unique biology shows great potential for disease prevention because it can be influenced by certain exposures, particularly hormones. Also, the KRAS-variant is primarily associated with cancer onset at or after menopause. Understanding these two factors provides some guidance for disease risk mitigation to individuals with the KRAS-variant.
Learning whether you carry this the KRAS-Variant can help you make informed decisions about your health at many points in your life:
Determine whether higher-level breast cancer screening, such as breast MRI, is something to consider in addition to annual mammograms. If having a hysterectomy and you are peri-menopausal, discuss the pros and cons of ovary removal with follow-up hormone replacement therapy (HRT) with your physician.
Determine whether hormone replacement therapy at menopause could be protective against cancer if not otherwise contraindicated. Use the information to determine whether or not ovary removal makes sense for you at menopause.
Be aware that an increased risk of ovarian cancer increases the importance of ongoing gynecological care. Determine whether continuing on hormone replacement therapy may be beneficial.
Use your genetic information to ask for continued breast and gynecological screening. Determine whether continuing on hormone replacement therapy may be beneficial.